CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the genetic mechanisms behind resistance to targeted therapies in acute myeloid leukemia (AML). By utilizing advanced genetic screening and transcriptome profiling techniques, it aims to identify new therapeutic targets and develop combination therapies to improve patient outcomes.
In the last decade, we have witnessed tremendous progress in understanding the genetic landscape of acute myeloid leukemia (AML), which has been translated into several approved targeted therapies.
Although these therapies are effective initially, most patients eventually develop resistance through a variety of genetic and/or epigenetic mechanisms that remain incompletely understood.
While it is widely accepted that transient responses to oncogene-targeted therapeutics into cure will require dru…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
